Lexicon Pharmaceuticals | LXRX - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Abbott USD 6.8B 1.72B 2026-03
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Akebia Therapeutics USD 162.64M 22.2M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
AstraZeneca USD 7.56B 1.85B 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Illumina USD 1.42B 368M 2025-12
Insmed USD 582.19M 71.74M 2026-03
Ironwood Pharmaceuticals USD 220.47M 5.01M 2026-03
J&J USD 21.69B 1.98B 2026-03
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
MacroGenics USD 66.52M 9.3M 2026-03
MannKind USD 52.83M 22.05M 2026-03
Merck USD 5.33B 9.24B 2026-03
Moderna USD 1.91B 687M 2026-03
Novartis USD 6.88B 4.56B 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Thermo Fisher Scientific USD 3.25B 6.6B 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12